Method for the treatment of lipid and glucose metabolism disorders
AssigneePliva D.D.
InventorAnthony H. Cincotta
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for modifying or regulating at least one of glucose or lipid metabolism disorders which comprises administering to a human or vertebrate subject a D1 dopamine agonist in conjunction with a dopamine D2 agonist where the conjoined administration is effective to improve at least one of the following lipid and glucose metabolic indices: body weight, body fat, plasma insulin, plasma glucose and plasma lipid, and plasma lipoprotein. In preferred embodiments, the administration of the D1 dopamine agonist and the D2 dopamine agonist is conducted at a predetermined time.
Claims14
A method for modifying or regulating at least one of glucose or lipid metabolism disorders which comprises administering to a human or vertebrate animal subject in need of such modification or regulation D1 dopamine agonist 1-phenyl-2,3,4,5-tetrahydro-[1H]-benzazepine-7,8-diol, or a pharmaceutically acceptable salt thereof, in conjunction with an ergot alkaloid dopamine D2 agonist wherein the conjoined administration is effective to improve at least one of the following lipid and glucose metabolic indices:
- body weight, body fat, plasma insulin, plasma glucose and plasma lipid, and plasma lipoprotein.
Dependencies are inferred from the claim text.